Cutaneous T-Cell Lymphoma
Journal of Clinical Oncology Publishes Data on ZOLINZA (vorinostat), Merck's Treatment for Advanced Cutaneous T-cell Lymphoma
Published in Blood Weekly, August 9th, 2007
Results from a clinical study conducted with patients who were diagnosed with advanced, refractory cutaneous T-cell lymphoma (CTCL) showed nearly a third of patients responded to treatment with ZOLINZA(TM) (vorinostat), as measured by objective response rate, according to data published in this week's Journal of Clinical Oncology. ZOLINZA, Merck's most recent anticancer treatment, is approved for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent or recurrent disease on or following two systemic therapies. CTCL is a cancer of the T-cells, a type of white blood cell, which affects the skin and is a form of non-Hodgkin's lymphoma.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-08-09)
More Articles from Blood Weekly
- Cancer
Cancer risk does not increase for recipients of blood transfusions from donors with undiagnosed cancer - Sickle Cell Anemia
Red Cell Substitute Shows Promise as Treatment for Sickle Cell Disease - Artificial Organs
German and French CardioWest Artificial Heart Patients Enjoy a Better Quality of Life Than Americans - Cerus Corporation
Grifols S.A. and Cerus Corporation Agree to Commercialize the INTERCEPT Blood System in Spain and Portugal - Clinical and Laboratory Standards Institute (CLSI)
CLSI Publishes Guideline on Platelet Function Testing by Aggregometry - Cord Blood
A Market Insight into the Progressing and Debatable Market of Stem Cell Research - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
